BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 31605163)

  • 1. Role of stereotactic body radiation therapy in the treatment of liver metastases: clinical results and prognostic factors.
    Clerici E; Comito T; Franzese C; Di Brina L; Tozzi A; Iftode C; Navarria P; Mancosu P; Reggiori G; Tomatis S; Scorsetti M
    Strahlenther Onkol; 2020 Apr; 196(4):325-333. PubMed ID: 31605163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up.
    Scorsetti M; Comito T; Clerici E; Franzese C; Tozzi A; Iftode C; Di Brina L; Navarria P; Mancosu P; Reggiori G; Fogliata A; Tomatis S; Torzilli G; Cozzi L
    Radiat Oncol; 2018 Nov; 13(1):234. PubMed ID: 30477560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of Stereotactic Body Radiation Therapy for patient with unresectable liver metastases from colorectal cancer.
    Py JF; Salleron J; Courrech F; Beckendorf V; Croisé-Laurent V; Peiffert D; Vogin G; Dietmann AS
    Cancer Radiother; 2021 Jun; 25(4):350-357. PubMed ID: 33618909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy.
    Franzese C; Comito T; Franceschini D; Loi M; Clerici E; Navarria P; De Rose F; Di Brina L; Mancosu P; Reggiori G; Tomatis S; Scorsetti M
    J Cancer Res Clin Oncol; 2020 May; 146(5):1227-1234. PubMed ID: 32056005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases.
    Fumagalli I; Bibault JE; Dewas S; Kramar A; Mirabel X; Prevost B; Lacornerie T; Jerraya H; Lartigau E
    Radiat Oncol; 2012 Sep; 7():164. PubMed ID: 23014094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases.
    Klement RJ; Abbasi-Senger N; Adebahr S; Alheid H; Allgaeuer M; Becker G; Blanck O; Boda-Heggemann J; Brunner T; Duma M; Eble MJ; Ernst I; Gerum S; Habermehl D; Hass P; Henkenberens C; Hildebrandt G; Imhoff D; Kahl H; Klass ND; Krempien R; Lewitzki V; Lohaus F; Ostheimer C; Papachristofilou A; Petersen C; Rieber J; Schneider T; Schrade E; Semrau R; Wachter S; Wittig A; Guckenberger M; Andratschke N
    BMC Cancer; 2019 Feb; 19(1):173. PubMed ID: 30808323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease.
    Osti MF; Agolli L; Valeriani M; Reverberi C; Bracci S; Marinelli L; De Sanctis V; Cortesi E; Martelli M; De Dominicis C; Minniti G; Nicosia L
    Lung Cancer; 2018 Aug; 122():165-170. PubMed ID: 30032826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional chemotherapy improved local control and overall survival after stereotactic body radiation therapy for patients with oligo-recurrence.
    Nakamura M; Hashimoto N; Mayahara H; Uezono H; Harada A; Nishikawa R; Matsuo Y; Kawaguchi H; Nishimura H
    Radiat Oncol; 2018 Apr; 13(1):75. PubMed ID: 29688858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
    Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
    Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy.
    Franzese C; Comito T; Toska E; Tozzi A; Clerici E; De Rose F; Franceschini D; Navarria P; Reggiori G; Tomatis S; Scorsetti M
    Radiother Oncol; 2019 Apr; 133():220-226. PubMed ID: 30414754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic Body Radiation Therapy (SBRT) Using CyberKnife in Oligometastatic Cancer Patients; Retrospective Evaluation, Single Institution Experience.
    Alsuhaibani A; Elashwah A; Alkafi A; Constantinescus C; ALzorkany F
    J Gastrointest Cancer; 2019 Dec; 50(4):879-887. PubMed ID: 30291546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases.
    Andratschke N; Alheid H; Allgäuer M; Becker G; Blanck O; Boda-Heggemann J; Brunner T; Duma M; Gerum S; Guckenberger M; Hildebrandt G; Klement RJ; Lewitzki V; Ostheimer C; Papachristofilou A; Petersen C; Schneider T; Semrau R; Wachter S; Habermehl D
    BMC Cancer; 2018 Mar; 18(1):283. PubMed ID: 29534687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiosurgery and fractionated stereotactic body radiotherapy for patients with lung oligometastases.
    Kalinauskaite GG; Tinhofer II; Kufeld MM; Kluge AA; Grün AA; Budach VV; Senger CC; Stromberger CC
    BMC Cancer; 2020 May; 20(1):404. PubMed ID: 32393261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcomes of breast cancer liver metastasis treated with stereotactic body radiotherapy.
    Onal C; Guler OC; Yildirim BA
    Breast; 2018 Dec; 42():150-156. PubMed ID: 30296648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry.
    Mahadevan A; Blanck O; Lanciano R; Peddada A; Sundararaman S; D'Ambrosio D; Sharma S; Perry D; Kolker J; Davis J
    Radiat Oncol; 2018 Feb; 13(1):26. PubMed ID: 29439707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
    Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
    Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.
    Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF
    Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients.
    König L; Häfner MF; Katayama S; Koerber SA; Tonndorf-Martini E; Bernhardt D; von Nettelbladt B; Weykamp F; Hoegen P; Klüter S; Susko MS; Debus J; Hörner-Rieber J
    Radiat Oncol; 2020 Feb; 15(1):30. PubMed ID: 32019553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT).
    Scorsetti M; Comito T; Cozzi L; Clerici E; Tozzi A; Franzese C; Navarria P; Fogliata A; Tomatis S; D'Agostino G; Iftode C; Mancosu P; Ceriani R; Torzilli G
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1301-9. PubMed ID: 25644863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy.
    Jang WI; Bae SH; Kim MS; Han CJ; Park SC; Kim SB; Cho EH; Choi CW; Kim KS; Hwang S; Kim JH; Chang AR; Park Y; Kim ES; Kim WC; Jo S; Park HJ
    Cancer; 2020 Jan; 126(2):363-372. PubMed ID: 31747476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.